Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
Sponsor: LENZ Therapeutics, Inc
Summary
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
Official title: A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
Key Details
Gender
All
Age Range
45 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
469
Start Date
2022-12-19
Completion Date
2024-01-25
Last Updated
2026-05-13
Healthy Volunteers
Yes
Interventions
Aceclidine+Brimonidine combination ophthalmic solution
LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
Aceclidine ophthalmic solution
LNZ100 Aceclidine ophthalmic solution
Brimonidine
Brimonidine ophthalmic solution
Locations (25)
Site #106
Chandler, Arizona, United States
Site #121
Mesa, Arizona, United States
Site #122
Phoenix, Arizona, United States
Site #124
Phoenix, Arizona, United States
Site #128
Scottsdale, Arizona, United States
Site #125
Sun City, Arizona, United States
Site #130
Azusa, California, United States
Site #110
Garden Grove, California, United States
Site #101
Glendale, California, United States
Site #129
Newport Beach, California, United States
Site #107
Petaluma, California, United States
Site #126
Rancho Cordova, California, United States
Site #111
Santa Barbara, California, United States
Site #109
Littleton, Colorado, United States
Site #102
Mt. Dora, Florida, United States
Site #118
Rock Island, Illinois, United States
Site #127
Overland Park, Kansas, United States
Site #108
Pittsburg, Kansas, United States
Site #131
Rochester, New York, United States
Site #104
Fargo, North Dakota, United States
Site #103
Kingston, Pennsylvania, United States
Site #116
Memphis, Tennessee, United States
Site #112
Smyrna, Tennessee, United States
Site #119
San Antonio, Texas, United States
Site #123
San Antonio, Texas, United States